Market Overview

UPDATE: Morgan Stanley Upgrades Alkermes plc to Overweight on New Pipeline Opportunities

Share:
Related ALKS
Why Citigroup Placed An $85 Price Target On Shares Of Alkermes
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
Egalet up on HAL study (Seeking Alpha)

Morgan Stanley upgraded Alkermes plc (NASDAQ: ALKS) from Equal-weight to Overweight and raised the price target from $21.00 to $26.00.

Morgan Stanley noted, "We anticipate improving investor perception as Alkermes transitions from being an outsourced drug delivery tech co. to an innovation engine with higher-value internal candidates. … We added a key new pipeline drug (3831 for schizophrenia) due to new disclosure Jan. 4, and we have greater conviction that Alkermes can develop new drugs to offset patent expirations in 2019 and beyond."

Alkermes plc closed at $21.61 on Wednesday.

Latest Ratings for ALKS

DateFirmActionFromTo
Jan 2015CitigroupMaintainsBuy
Dec 2014CitigroupMaintainsBuy
Dec 2014Credit SuisseMaintainsOutperform

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ALKS)

Around the Web, We're Loving...

Get Benzinga's Newsletters